Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

Sandoz and Regeneron reach agreement over biosimilar dispute

Professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland

Videos

Using OCT-A to explore biomarkers for neurodegenerative diseases

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

UnitedHealthcare updates Glaucoma Surgical Treatments policy

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

The 14th annual Glaucoma 360 conference will take place February 6 to 8, 2025, at the Westin St. Francis on Union Square in San Francisco, California. Co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, the three-day event highlights progress in glaucoma care while fostering innovation and collaboration.

The conference opens on Thursday, February 6, with a gala to celebrate advancements in the field, followed by the New Horizons Forum on Friday, February 7, which serves as an incubator for innovation. Topics include artificial intelligence in glaucoma management, neuroprotection and vision restoration, and cross-species insights from veterinary ophthalmology. Carla J. Siegfried, MD, president of the American Glaucoma Society, will deliver the keynote address.

The program on Saturday, February 8, begins with a continuing medical education program featuring M. Roy Wilson, MD, MS, who will present the Shaffer-Hetherington-Hoskins Lecture, and concludes with an optometric symposium. Visit 

SAP Partner

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-friendly, multispecialty CME ophthalmology conference, along with a newly introduced optometry track. Henderson sits down with 

' Sheryl Stevenson, group editorial director - eye care, to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Henderson describes the meeting as “a place where not only are physicians and optometrists learning, but their families are part of the experience too,” emphasizing the opportunity for personal and professional growth in a supportive, community-oriented environment.

The 2025 agenda will include symposia, surgical videos, panel discussions, and leadership seminars that highlight rapid advancements across ophthalmology specialties, including cataract, refractive, retina, glaucoma, pediatrics, and oculoplastics. “It’s incredible how quickly things change in ophthalmology—if you miss a year or two, you’ll be amazed by the innovations that have emerged,” Henderson shared. Updates on new intraocular lenses, surgical tools, and diagnostic techniques will showcase the field’s forward momentum. Additionally, a leadership seminar led by Malvina Eydelman, MD, Director of the Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices at FDA, Silver Spring, Maryland, will feature discussions on career pathways and diversity, empowering attendees with insights from industry leaders.

The optometry track, introduced last year, continues to expand, emphasizing collaboration between ophthalmologists and optometrists in critical areas like preoperative and postoperative care, medications, and diagnostic tools. As Henderson explained, “It's important for both fields to come together and discuss how we can work together to improve patient care.” This cross-disciplinary dialogue reflects the summit's dedication to advancing care through shared expertise.

The youth program offers age-appropriate activities that allow children to engage in fun learning while also witnessing their parents' professional contributions. "It’s amazing to watch these kids grow up at EnVision Summit and form lasting friendships,” said Henderson. The trainee program, which offers free registration for residents, fellows, and medical students, has also seen growth. Henderson highlighted the program’s value, noting that it “gives young professionals the chance to network with leaders in the field and gain invaluable mentorship.”



To learn more about or to register for EnVision Summit 2025,

EnVision Summit

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Connect, learn, and innovate in a family-friendly atmosphere:  What to expect at EnVision Summit 2025

 podcast, Robert T. Chang, MD, from Stanford University, discusses the role of large language models (LLMs) and AI in ophthalmology. He explains how LLMs, like ChatGPT, are transforming information retrieval, patient communication, and education.

Chang emphasizes how AI assists clinicians in documenting patient interactions, creating customized educational content, and exploring potential future uses, such as efficient data aggregation for research. He also addresses challenges, including ethical concerns around data privacy and the need for clinicians to verify AI outputs. 

Chang highlights how LLMs could streamline workflows and support both patient care and professional training, offering a promising, albeit cautious, outlook on AI's impact in ophthalmology.

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing patient communication, documentation, and education, while also addressing ethical considerations and potential future applications in glaucoma care.

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

In this EyePod® episode, Peter J. McDonnell, MD, and Neda Shamie, MD, discuss the transformative impact of minimally invasive glaucoma surgery (MIGS) on glaucoma care and its integration with cataract surgery, sharing insights and practical tips for ophthalmologists.

The views and perspectives expressed are those of Dr. McDonnell and Dr. Shamie.

This transcript has been edited for clarity.

Hi, everyone! Welcome to this episode of the 

This is Sheryl Stevenson, group editorial director with 

, and we are joined today by our co-chief medical editors.

Dr. Peter J. McDonnell is the director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr. Neda Shamie is a cataract, LASIK, and corneal surgeon and partner of the Maloney-Shamie Vision Institute in Los Angeles, California, as well as an adjunct clinical professor of ophthalmology at the USC Keck School of Medicine.

In today’s episode, they discuss how embracing MIGS procedures can significantly enhance glaucoma management during cataract surgeries, offering patients the opportunity to reduce their reliance on eye drops and improve overall treatment outcomes. They share how integrating MIGS into clinical practice can be a rewarding endeavor that empowers ophthalmologists to provide more effective care for patients with glaucoma.

 Welcome, everyone! This is Neda Shamie and you are listening to EyePod, which is sponsored by 

, where we talk about topics at hand in ophthalmology and really kind of bring it to the forefront of your thoughts so that you can explore further.

It's going to be a short conversation that I will be having with Dr. Peter McDonnell, who is my mentor, a dear friend, and someone who is truly an expert in the field of ophthalmology and I turn to for advice all the time. Hi, Peter!

 Hi, Neda! It's great to be here with my co-chief medical editor of 

 and talk about a really exciting thing that, I think, taking the world of glaucoma by storm, which are these great new MIGS devices. It's really caused in evolution in glaucoma care in the United States. And you've had very positive experience yourself with these devices, right?

 Yes, most definitely. I agree with you. I think in glaucoma, there's been a real significant paradigm shift since the advent of different MIGS devices that have allowed for a minimally invasive approach to treating glaucoma. When I was in my training, it was either [eye] drops or maybe some laser treatments, but ultimately, trabeculectomies and trabeculotomies and tubes and shunts and such, which have a lot of comorbidity associated with them. 

These minimally invasive glaucoma shunts and procedures that are done often at the same time as cataract surgery can really have very little added risks to the surgery, but have significant impact on glaucoma management of patients, lessen the load of the eye drops and the toxicity that go along with them. And really a wonderful addition to the armamentarium of not just glaucoma surgeons, but also cataract surgeons. And I think that's where we should really emphasize our discussion on. 

There's no question that glaucoma surgeons, at least the ones I speak to, are huge advocates of the advanced technology in the MIGS procedures. I think the challenge is that the gatekeepers are often the general eye doctors and cataract surgeons. And a lot of the time when these patients who have glaucoma and comorbidities associated with glaucoma, when they're ready to have cataract surgery and they have the opportunity to be a candidate for the MIGS, the MIGS procedures are not necessarily offered to them. 

I think the hurdle is to get past that because there's not enough glaucoma surgeons out there to really take care of all of the glaucoma patients out there. And often the feedback I'm getting from glaucoma surgeons is they really want us cataract surgeons to consider MIGS procedures at the time of our cataract surgery to lessen the burden of glaucoma for these patients and, hopefully, prevent progressive disease for them. 

 You know, I think you hit on a lot of really key points there. When I look at the data from the Academy's IRIS Registry [Intelligent Research in Sight] and also the Medicare database, 75% or more of glaucoma surgical procedures now are MIGS. And in this recent report only 13% were trabs. In my day, that was pretty much the glaucoma operation. 

And from my perspective, it was sort of for a refractive surgeon to do this 'loosey-goosey' tighten the sutures enough but not too much, etc. It was sort of imprecise. To me, there's lots of appeal of these MIGS and to see it go from very little to such a high percentage, almost 80% now of glaucoma surgical procedures are MIGS. That's really impressive. I'm wondering, in terms of getting people who are not glaucoma specialists and don't have much experience yet, and maybe there's a little trepidation about how to get started. 

What pearls would you offer? How did you make that transition to get going?

 Often, what happens with new additions to our surgical armamentarium, it's a patient that encourages us to forge ahead. 

I had a patient who had glaucoma who came to me [and] really wanted to have her cataract surgery done by me and was on 3 [eye] drops for glaucoma management. She's the one who said — this is a while ago, this is probably nearly 8 years ago — why aren't you offering me MIGS. Truthfully, she put me to shame because there was enough evidence for the benefits that iStent at the time was offering that I should have offered it together with a cataract surgery. And so I was very honest and transparent with her. And I said, I have not done one. And she says, why don't you have my case be your first. It really just takes that motivation. 

It takes that incentive to really want to do the best for your patients to bring on new technology. There is no question that the technology has now been proven to be effective. And the truth of the matter is, what do you have to lose and that's my attitude to my colleagues who push back on MIGS. You have really nothing to lose and everything to gain for your patients. 

To bring on the MIGS procedures it's a very simple addition to your surgery. The learning curve is very, very quick. For those of us who do a lot of anterior segment surgeries, having the ability to do that gonio visualization of the angle, and being able to maneuver in the anterior chamber is not very different than what we do in our preop exams. And we all know how to use a gonio lens. And it doesn't take much to learn how to do it in intraoperatively. And we all know how to maneuver in the eye without collateral damage to structures inside the eye. 

So I would say if there's trepidation, look at the data. Like anything, I do my research. I look at the data. I ask colleagues who have experience. And now with YouTube, 

, all the different resources available to really get as much information ahead of time as possible it again shouldn't take much to forge ahead.

I would suggest starting with one device first, getting familiar with probably the simplest device, which for me, at least, it was the iStent, but for others, it may be different approaches. And then from there moving forward. I think probably the biggest challenge is how to use the gonio intraoperatively. And then kind of understanding what the postoperative management of these patients are. 

It just simply took me communicating with colleagues and friends who've done a lot of these and getting their protocols in place. I feel great about offering it to my patients. I think as a cataract surgeon you're doing your patient disservice if they come in with glaucoma and they’re on at least 1 if not 2 drops and not offer them MIGS you have taken away an opportunity for them to be able to lessen their dependency on glaucoma drops.

I think those are all great pearls. The risk:benefit, I agree, is very much in favor of the benefit. We don't see the really feared complications of hypotony with the MIGS devices, so that's really nice. Now, it is true that a few years ago, Alcon did voluntarily recall the CyPass MIGS device because of concerns regarding endothelial cell loss...progressive endothelial cell loss. As two cornea specialists, you and I both love endothelial cells and we know they're important. But beyond that, I think the track record over the years has really been pretty darn positive in terms of relatively few adverse events and I think that's really helped support the increasing use over time.

And I think all the points you made are excellent. I guess if I was still concerned about getting started, I might ask a colleague who is available that day...maybe is also operating at the ASC...to sit there next to me while I do my first one or two cases or any tricks. Someone who has experience with using the MIGS. I can't agree with you more that starting with one and then getting comfortable and then moving on makes sense.

 In my practice, I don't have necessarily a go-to but I offer the iStent infinite, the Hydrus, and Omni canaloplasty and I kind of mix and match based on the degree of the patient's glaucoma, their dependence on drops, and I would say probably the biggest challenge and the steepest or the hardest learning curve really is how to fit the different options in your practice, how to present it to the patients, where does it land in your discussion and counseling of patients, and most importantly, how do you manage the postop. 

Again, there's very different kind of varied ways of doing all of that. In our practice, we have trained our technicians to be familiar with all the different technologies available and to present the options to our patients as they come in right at the same time as they discuss cataract surgery with our patients and educate them and then flag the chart so that I know to talk about the different MIGS procedures when I go in. 

And then postop, we have the patients continue to go through glaucoma eye drops until they're off of their steroid eye drops after which then we remove, we have 1 drop removed at a time of the glaucoma drops with a 1-month time to really kind of gauge what the pressure response would be. If a patient is comanaged, which many of my patients are, our comanaging doctors are well trained on how to do that. 

I feel great about really being at the forefront of this technology and I have had great results being able to lessen the burden of glaucoma drops for my patients. And that's key I think to create just like anything else have the expectations be realistic that this is not going to cure them of glaucoma, it's only going to help with management and potentially lessen their burden of the drops, maybe 1 possibly more than 1 drops.

So with that, I think, hopefully, for those listeners out there, you're convinced to at least explore the option of MIGS and adding that to your practice. Because after all, we're here to offer our patients the best treatment options out there and this treatment has been shown to be proven effective and safe. A patient who has glaucoma together with their cataract deserve to be offered this. By the way, I should also state that their Omni can also be offered without cataract surgery. So that's one treatment option...one of the MIGS procedures that can be done standalone, which, in itself, is an excellent opportunity to lessen the burden of glaucoma on our patients.

Thank you so much, Peter, for a wonderful discussion. I look forward to our next one.

 Always a pleasure, Neda. I love these stories of innovation in ophthalmology. It's a great field. 

You'll remember, you and I in our younger days, we were colleagues with George Baerveldt. He was, of course, the author of the Baerveldt Implant and he was a great innovator and he was careful and scientific in his approach, but it's great to see what I think is this dramatic, exciting development in terms of improving our management for glaucoma patients. I'm very positive about it. Very happy to see it.

Peter J. McDonnell, MD, and Neda Shamie, MD, discuss the transformative impact of minimally invasive glaucoma surgery (MIGS) on glaucoma care and its integration with cataract surgery, sharing insights and practical tips for ophthalmologists.

EyePod: Transforming the MIGS pipeline into clinical reality

Optimizing and modifying new glaucoma surgeries

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.

Modifying and optimizing a new era of glaucoma surgeries

Sahar Bedrood, MD, PhD, glaucoma and cataract specialist at Acuity Eye Group (Pasadena, CA), clinical assistant professor at USC Roski Eye Institute, shares her clinical perspective on the evolution of interventional glaucoma, including the shift in standard treatment procedures and why taking an active approach to treating patients is key for success.

In this latest EyePod® episode, Sahar Bedrood, MD, PhD, shares her clinical perspective on the multi-faceted, dynamic evolution of interventional glaucoma. 

Exploring the evolution of interventional glaucoma



During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Comparing micro-bypass implant + phaco vs phaco in POAG

A study reveals Hispanic patients face lower success rates in trabeculectomy with MMC compared to European patients, highlighting significant disparities in glaucoma surgery outcomes.

Hispanic patients with POAG had lower success rates after glaucoma surgery compared with patients of European descent

Dr. Tanna will kick off the new monthly subspecialty education series with a virtual session on September 9, 2025, focused on using OCT imaging and perimetry to track glaucoma progression.

Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series

New World Medical launches non-valved glaucoma drainage device, Ahmed ClearPath ST

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

Glaucoma techniques advance with innovative viscoelastic delivery

EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning

Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care.

To learn more about or to register for EyeCon 2025, 

Here’s one way to carry the summertime vibe into the fall: The 2025 

 EyeCon® conference is set for September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida. Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas, is a member of this year’s EyeCon educational committee, which also includes Joseph Allen, OD, FAAO, Dipl ABO; Sruthi Arepalli, MD; and Jade Coats, OD, FAAO. Together, they’ve crafted a program designed to foster dynamic, cross-disciplinary discussion between ophthalmologists and optometrists. 

This year’s agenda covers a wide range of topics, offering key insights into the latest diagnostic strategies and clinical trial data across specialties. Additionally, this year’s format represents a shift from past meetings, with the introduction of an educational committee, rather than individual chairs, overseeing the structure and direction of sessions.

Smith, who will help lead a glaucoma session, recently sat down with the 

 to share a sample of what attendees can expect. She noted that it has been just over a decade since the first minimally invasive glaucoma surgery (MIGS) procedures, such as the iStent, were introduced around 2012, marking an important milestone in the field. She added, “We’ve come full circle, sort of learning all the different MIGS procedures that have come out, and then we’re at the place now where we’re trying to look at each procedure and its long-term effects in reducing IOP and preserving vision.”

The session will highlight phase 3 clinical trials that demonstrate the benefits of MIGS and explore broader shifts in glaucoma management. One key example is the LiGHT trial, which provided evidence for early intervention strategies.

Smith emphasized the importance of both timely care and communication between specialists across a patient’s care journey. “Glaucoma patients have disease for the long term. They sometimes see different specialists over their lifetime. One of the things I always say works well for any patient that has a chronic disease is communication, making sure we get records or we exchange records as new things occur.”

Looking ahead, Smith sees the field moving toward earlier, less-invasive treatment options and greater collaboration in co-management. “There is a big burden of glaucoma. We are well aware of that, and that over time that burden will only increase. With that going on then the burden to take care of these patients is there, and for us to do a better job taking care of patients and not referring them later on in their disease, but early on when we can push back some of the more invasive interventions that we have available like trabeculectomies and tube shunts.”

The EyeCon meeting will feature what Smith calls structured “program pods” to foster focused discussion, as well as a collaborative environment where ophthalmologists and optometrists can address shared challenges in patient care. The exhibit hall will also provide opportunities to engage with industry partners and learn about new technologies.

Smith noted that the venue itself encourages balance: “Fun location. You can bring your family along with you. You spend portions of the day learning, and then you’re able to spend time doing things that are more social in that environment, spending time on the beach.”

Most importantly, she stressed that the educational committee’s goal is for attendees to leave with practical insights they can implement immediately. “One thing we always like to say as the educational committee is to make sure we provide substance that allows people to go home and come Monday morning when they show up at their offices, there are certain things they’ve learned at the meeting that they can use on day 1.”

Smith O, Stevenson S, Hayes H. ASCRS 2025: Oluwatosin U. Smith, MD, champions early intervention and innovative glaucoma technologies. 

. April 25, 2025. Accessed August 18, 2025. 

https://www.ophthalmologytimes.com/view/ascrs-2025-oluwatosin-u-smith-md-champions-early-intervention-and-innovative-glaucoma-technologies

Charters L. AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years. 

. October 20, 2024. Accessed August 18, 2025. 

https://www.ophthalmologytimes.com/view/aao-2024-light-trial-shows-slt-outperforms-medications-in-reducing-glaucoma-progression-over-6-years

Extend the summer at EyeCon 2025—where clinical insight meets coastal vibes—September 26 and 27 at the Margaritaville Hollywood Beach Resort in Florida.

Accelerating eye health innovation through CCOI – Stanford Summit

On July 23, 2025, the Ophthalmic Innovation Symposium and Workshop 2025: From Concept to Clinic will take place at Stanford University in Palo Alto, California. Presented by the Bay Area Ophthalmology Consortium and the Byers Eye Institute at the Stanford University School of Medicine—in conjunction with the Collaborative Community on Ophthalmic Innovation (CCOI)—this event is set to unite leaders from across the eye care ecosystem to accelerate impactful innovation.

Led by Malvina Eydelman, MD, chief executive officer, the CCOI portion of the program will explore a wide range of critical themes. Among the presenters is Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, who recently sat down with 

 to offer a preview of what his presentation will focus on regarding accelerating eye health innovations through CCOI. “It’s never dull in our space,” Mazzo quipped, “and I would say that is true—my forty-seventh year in this space.”

Mazzo will spotlight a pressing paradox: despite remarkable strides in diagnostics and surgical precision, global blindness continues to rise. “If I was a patient—which I am—why is blindness still a tremendous problem for us?” he asked. His answer points to the systemic siloing of innovation. “You’ve got researchers, you’ve got clinicians, you’ve got engineers, and obviously the end user, the patient, all kind of working in isolation.”

CCOI, Mazzo highlighted, is stepping in to unify stakeholders through a “global inclusive and transparent ecosystem,” one that harmonizes regulators, payers, innovators, and clinicians. “Align the incentives,” he said. “When incentives are aligned in any business, it’s dramatic change.”

The summit will also highlight emerging enablers like AI, real-world evidence, and smart diagnostics. “We have these unbelievable, as I call them now, smart diagnostics,” Mazzo noted, “and they need to be embedded in these ecosystems.”

Ultimately, Mazzo calls on all ophthalmology stakeholders—policymakers, startup founders, researchers, and patient advocates—to engage with CCOI’s mission. “We can't solve these vision challenges with yesterday’s innovation model,” he said. “If we don’t break these barriers and move these silos together, we’re never going to get to what the patient requires today.”

Jim Mazzo is among the presenters who will highlight the need to break silos and accelerate eye health solutions at the Collaborative Community on Ophthalmic Innovation (CCOI) meeting at Stanford University on July 23, 2025.

50 years of ophthalmology: What changed the game (Part 2)

 50th anniversary celebration, anterior segment surgeons at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 annual meeting in Los Angeles, California, shared their perspectives on the most impactful innovations in ophthalmology over the past five decades.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

Interventional Glaucoma

Latest News